TY  - JOUR
AU  - Galldiks, Norbert
AU  - Lohmann, Philipp
AU  - Langen, Karl-Josef
TI  - Imaging challenges following newer treatment options: Are companion diagnostics required in neurooncology?
JO  - Expert review of molecular diagnostics
VL  - 20
IS  - 7
SN  - 1744-8352
CY  - Abingdon
PB  - Taylor & Francis Group
M1  - FZJ-2020-02401
SP  - 651-652
PY  - 2020
AB  - Contrast-enhanced MRI is the method of choice for follow-up imaging in patients with brain tumors, but its specificity is low despite outstanding spatial resolution [1,2]. Importantly, the differentiation of treatment-related changes from actual tumor progression following newer treatment options such as immunotherapy using checkpoint inhibitors or vaccines is challenging by anatomical MRI alone [2–4]. Specifically, inflammation with intratumoral T-cell infiltrates triggered by immunotherapy may lead to highly variable MR imaging findings including contrast enhancement that may suggest tumor progression. Moreover, neuroimaging changes induced by these treatment options may also hamper a reliable response assessment.
LB  - PUB:(DE-HGF)16
C6  - pmid:32552245
UR  - <Go to ISI:>//WOS:000549555100001
DO  - DOI:10.1080/14737159.2020.1782191
UR  - https://juser.fz-juelich.de/record/877691
ER  -